AbbVie Inc. (ABBV) vs AstraZeneca PLC (AZN)
AbbVie Inc. and AstraZeneca PLC are both Drug Manufacturers General companies. AbbVie Inc. is the larger, with a market value of $467.4B against $257.8B — 1.8× the size. AstraZeneca PLC trades at the lower P/E: 24.7× against 74.7×. AbbVie Inc. grew revenue faster over the last twelve months: 10.4% against 8.61%. AstraZeneca PLC has the higher net margin (17.0% vs 9.74%) and the lower return on invested capital (11.7% vs 18.1%). Both pay a dividend; AbbVie Inc. yields more (3.57% vs 2.49%). Across the 22 metrics below, AstraZeneca PLC leads on 14 and AbbVie Inc. on 8.
Valuation
Profitability
| Metric | ABBV | AZN | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 71.48% | 81.88% | 72.77% |
| Operating margin | 26.20% | 22.77% | 18.90% |
| Net margin | 9.74% | 17.02% | 8.27% |
| Free cash flow margin | 28.28% | 10.21% | 17.25% |
| Return on equity | (208.10%) | 21.95% | 6.97% |
| Return on assets | 4.61% | 9.15% | 2.76% |
| Return on invested capital | 18.07% | 11.67% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack